Abstract:BACKGROUND:The human papillomavirus (HPV) E2 protein is a multifunctional DNA-binding protein. The transcriptional activity of HPV E2 is mediated by binding to its specific binding sites in the upstream regulatory region of the HPV genomes. Previously we reported a HPV-2 variant from a verrucae vulgaris patient with huge extensive clustered cutaneous, which have five point mutations in its E2 ORF, L118S, S235P, Y287H, S293R and A338V. Under the control of HPV-2 LCR, co-expression of the mutated HPV E2 induced an increased activity on the viral early promoter. In the present study, a series of mammalian expression plasmids encoding E2 proteins with one to five amino acid (aa) substitutions for these mutations were constructed and transfected into HeLa, C33A and SiHa cells.RESULTS:CAT expression assays indicated that the enhanced promoter activity was due to the co-expressions of the E2 constructs containing A338V mutation within the DNA-binding domain. Western blots analysis demonstrated that the transiently transfected E2 expressing plasmids, regardless of prototype or the A338V mutant, were continuously expressed in the cells. To study the effect of E2 mutations on its DNA-binding activity, a serial of recombinant E2 proteins with various lengths were expressed and purified. Electrophoresis mobility shift assays (EMSA) showed that the binding affinity of E2 protein with A338V mutation to both an artificial probe with two E2 binding sites or HPV-2 and HPV-16 promoter-proximal LCR sequences were significantly stronger than that of the HPV-2 prototype E2. Furthermore, co-expression of the construct containing A338V mutant exhibited increased activities on heterologous HPV-16 early promoter P97 than that of prototype E2.CONCLUSIONS:These results suggest that the mutation from Ala to Val at aa 338 is critical for E2 DNA-binding and its transcriptional regulation.

Increasing the expression levels of papillomavirus major capsid protein in Escherichia coli by N-terminal deletion.

Stop Codon Mutagenesis for Homogenous Expression of Human Papillomavirus L1 Protein in Escherichia Coli.

Construction, Expression, Purification and Identification of Chimeric HPV16 E7-L1 Virus Like Particles

Enhanced Expression of Soluble Human Papillomavirus L1 Through Coexpression of Molecular Chaperonin in Escherichia Coli

Expression of human papillomavirus type 16 L1 protein in Escherichia coli: denaturation, renaturation, and self-assembly of virus-like particles in vitro.

Human Papillomavirus L1 Protein Expressed in Escherichia Coli Self-Assembles into Virus-Like Particles That Are Highly Immunogenic.

Engineering of Recombinant Human Papillomavirus 16 L1 Protein for Incorporation with para-Azido- L-Phenylalanine

N-terminal truncations on L1 proteins of human papillomaviruses promote their soluble expression in Escherichia coli and self-assembly in vitro

Recombinant Expression of Truncated Human Papillomavirus 58 L1 Protein with Molecular Chaperones in E.coli

Preparation and biological activity of human papillomavirus type 52 virus-like particles

[Cloning and Expressing of Human Papillomavirus 16 E7C Subgene].

[Prokaryotic Expression of HPV 16 L1 Gene and Identification of Its Immune Activity].

Production of human papillomavirus type 16 virus-like particles and its immunogenicity]

A novel C-terminal modification method enhanced the yield of human papillomavirus L1 or chimeric L1-L2 virus-like particles in the baculovirus system

Expression of human papillomavirus type16 late gene (L1) in prokaryotic cells and its immune effict observation

Stable High-Level Expression of Truncated Human Papillomavirus Type 16 L1 Protein in Drosophila Schneider-2 Cells.

[Expression, Purification and Immunogenicity Analysis of HPV Type 18 Virus-Like Particles from Escherichia Coli].

Expression of Genetically Modified Human Papillomavirus Type 58 L1 Gene and Production of Antisera Against Resultant VLP

[Construction of Codon-Optimized HPV16 Capsid Genes in the Eukaryotic Co-Expression Vector and Transfection of Cells].

Prokaryotic Expression and Purification of Minor Capsid Protein L2 Derived from Human Papillomavirus 58 and Preparation of Monoclonal Antibody

A Point Mutation in the DNA-binding Domain of HPV-2 E2 Protein Increases Its DNA-binding Capacity and Reverses Its Transcriptional Regulatory Activity on the Viral Early Promoter.